13 — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00- HK$19.44bn
- HK$9.50bn
- $548.51m
UK Stocks-Factors to watch on September 3
HUTCHMED (China) signs exclusive licensing deal with GSK for investigational cancer drug
Brief: Hutchmed Announces Licensing Agreement With GSK For Kras-Egfr-Antibody Conjugate Cancer Therapy
UK Stocks-Factors to watch on September 1 (updated)
AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study (updated)
SANOVO trial demonstrated significant PFS benefit
Brief: HUTCHMED (China) Announces NMPA Conditional Approval For ATLED In China
NMPA Approval for ATLED® (Fanregratinib) for ICC
Brief: Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China
Announcement pursuant to AIM Rule 17 Schedule 2(g)
Orpathys+Tagrisso improved PFS & OS in EGFRm lung
HK's Hutchmed rises on progress of Orpathys Plus Tagrisso for cancer treatment
Brief: Hutchmed (China) Says Orpathys Plus Tagrisso Improves Survival In Egfr-Mutated Nsclc In Phase III Trial
HUTCHMED Reports 2026 Interim Results
HUTCHMED climbs after China approves ORPATHYS for gastric cancer treatment
Brief: HUTCHMED (China) Announces NMPA Conditional Approval For Orpathys For Met-Amplified Advanced Gastric Cancer In China
HUTCHMED Announces NMPA Approval for ORPATHYS
Hutchmed To Announce 2026 Half: Year Results
HUTCHMED Highlights Phase II Data at ESMO